nach oben

Annals of Hematology

Erschienen in:

25.05.2018 | Review Article

Treatment of classical Hodgkin lymphoma in the era of brentuximab vedotin and immune checkpoint inhibitors

verfasst von: A. M. Carella, P. Corradini, A. Mussetti, U. Ricardi, U. Vitolo, S. Viviani

Erschienen in: Annals of Hematology | Ausgabe 8/2018

Einloggen, um Zugang zu erhalten

Abstract

The majority of Hodgkin lymphoma patients are now cured with conventional first-line therapy; however, 10–15% of early-stage disease and less than 30% of advanced-stage patients are refractory(rare) or relapsed. Salvage second-line therapy combined with high-dose therapy and autologous stem-cell transplantation can cure 40–50% of patients. Recently novel agents (Brentuximab Vedotin and Immune Checkpoint inhibitors) have demonstrated evidence of therapeutic activity and are potential bridge to an allogeneic stem-cell transplantation. The review is aimed to present not only salvage strategies; indeed, the paper contains paragraphs about therapy and new treatment options at diagnosis.

Borchmann S, von Treskow B, Engert A (2016) Current developments in the treatment of early stage classical Hodgkin lymphoma. Curr Opin Oncol 28:377–383CrossRefPubMed

Engert A, Raemaekers J (2016 Jul) Tretament of early stage Hodgkin lymphoma. Semin Hematol 53(3):165–170CrossRefPubMed

Parikh RR, Groosbard ML, Harrison LB, Yahalom J (2015) Early-stage classic Hodgkin lymphoma: the utilization of radiation therapy and its impact on overall survival. Int J Radiat Oncol Biol Phys 93(3):684–693CrossRefPubMed

Specht L, Yahalom J (2015 Oct) The concept and evolution of involved site radiotherapy for lymphoma. Int J Clin Oncol 20(5):849–854CrossRefPubMed

Gallamini A, Hutchings M, Rigacci L, Specht L, Merli F, Hansen M, Patti C, Loft A, di Raimondo F, D'Amore F, Biggi A, Vitolo U, Stelitano C, Sancetta R, Trentin L, Luminari S, Iannitto E, Viviani S, Pierri I, Levis A (2007) Early interim 2-[18F]Fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin’s lymphoma: a report from a joint Italian-Danish study. J Clin Oncol 25(24):3746–3752CrossRefPubMed

Raemaekers JM, André MP, Federico M et al (2014) Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol 32(12):1188–1194CrossRefPubMed

André M, Girinsky T, Federico M et al (2017) Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol 35(16):1786–1794CrossRefPubMed

Radford J, Illidge T, Counsell N, Hancock B, Pettengell R, Johnson P, Wimperis J, Culligan D, Popova B, Smith P, McMillan A, Brownell A, Kruger A, Lister A, Hoskin P, O’Doherty M, Barrington S (2015) Results of a trial of PET-directed therapy for early-stage Hodgkin’s lymphoma. N Engl J Med 372(17):1598–1607CrossRefPubMed

Girinsky T, van der Maazen R, Specht L, Aleman B, Poortmans P, Lievens Y, Meijnders P, Ghalibafian M, Meerwaldt J, Noordijk E (2006) Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines. Radiother Oncol 79(3):270–277CrossRefPubMed

10.

van Nimwegen FA, Schaapveld M, Cutter DJ, Janus CPM, Krol ADG, Hauptmann M, Kooijman K, Roesink J, van der Maazen R, Darby SC, Aleman BMP, van Leeuwen FE (2016) Radiation dose-response relationship for risk of coronary heart disease in survivors of Hodgkin lymphoma. J Clin Oncol 34:235–243CrossRefPubMed

11.

Schaapveld M, Aleman BMP, van Eggermond AM, Janus CPM, Krol ADG, van der Maazen RWM, Roesink J, Raemaekers JMM, de Boer JP, Zijlstra JM, van Imhoff GW, Petersen EJ, Poortmans PMP, Beijert M, Lybeert ML, Mulder I, Visser O, Louwman MWJ, Krul IM, Lugtenburg PJ, van Leeuwen FE (2015) Second cancer risk up to 40 years after treatment for Hodgkin’s lymphoma. N Engl J Med 373(26):2499–2511CrossRefPubMed

12.

Yahalom J, Mauch P (2002) The involved field is back: issues in delineating the radiation field in Hodgkin’s disease. Ann Oncol 13(supplement 1):79–83CrossRefPubMed

13.

Specht L, Yahalom J, Illidge T, Berthelsen AK, Constine LS, Eich HT, Girinsky T, Hoppe RT, Mauch P, Mikhaeel NG, Ng A (2014) Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the international lymphoma radiation oncology group (ILROG). Int J Radiat Oncol Biol Phys 89(4):854–862CrossRefPubMed

14.

Campbell BA, Voss N, Pickles T, Morris J, Gascoyne RD, Savage KJ, Connors JM (2008) Involved-nodal radiation therapy as a component of combination therapy for limited-stage Hodgkin’s lymphoma: a question of field size. J Clin Oncol 26:5170–5174CrossRefPubMed

15.

Maraldo MV, Aznar MC, Vogelius IR, Petersen PM, Specht L (2013) Involved node radiation therapy: an effective alternative in early-stage Hodgkin’s lymphoma. Int J Radiat Oncol Biol Phys 85(4):1057–1065CrossRefPubMed

16.

Filippi AR, Ciammella P, Piva C, Ragona R, Botto B, Gavarotti P, Merli F, Vitolo U, Iotti C, Ricardi U (2014) Involved-site image-guided intensity-modulated radiotherapy vs. 3D conformal radiotherapy in supra-diaphragmatic early stage Hodgkin’s lymphoma. Int J Radiat Oncol Biol Phys 89(2):370–375CrossRefPubMed

17.

Fiandra C, Filippi AR, Catuzzo P, Botticella A, Ciammella P, Franco P, Borca V, Ragona R, Tofani S, Ricardi U (2012) Different IMRT solutions vs. 3D-conformal radiotherapy in early stage Hodgkin’s lymphoma: dosimetric comparison and clinical considerations. Radiat Oncol 7:186CrossRefPubMedPubMedCentral

18.

Maraldo MV, Dabaja BS, Filippi AR, Illidge T, Tsang R, Ricardi U, Petersen PM, Schut DA, Garcia J, Headley J, Parent A, Guibord B, Ragona R, Specht L (2015) Radiation therapy planning for early-stage Hodgkin lymphoma: experience of the international lymphoma radiation oncology group. Int J Radiat Oncol Biol Phys 92(1):144–152CrossRefPubMed

19.

Filippi AR, Ragona R, Piva C, Scafa D, Fiandra C, Fusella M, Giglioli FR, Lohr F, Ricardi U (2015) Optimized volumetric modulated arc therapy versus 3D-CRT for early stage mediastinal Hodgkin lymphoma without axillary involvement: a comparison of second cancers and heart disease risk. Int J Radiat Oncol Biol Phys 92(1):161–168CrossRefPubMed

20.

Voong KR, McSpadden K, Pinnix CC, Shihadeh F, Reed V, Salehpour MR, Arzu I, Wang H, Hodgson D, Garcia J, Aristophanous M, Dabaja BS (2014) Dosimetric advantages of a “butterfly” technique for intensity-modulated radiation therapy for young female patients with mediastinal Hodgkin’s lymphoma. Radiat Oncol 9:94CrossRefPubMedPubMedCentral

21.

Hoppe BS, Flampouri S, Su Z, Latif N, Dang NH, Lynch J, Joyce M, Sandler E, Li Z, Mendenhall NP (2012) Effective dose reduction to cardiac structures using protons compared with 3DCRT and IMRT in mediastinal Hodgkin lymphoma. Int J Radiat Oncol Biol Phys 84(2):449–455CrossRefPubMed

22.

Hoppe BS, Tsai H, Larson G, Laramore GE, Vargas C, Tseng YD, Dunn M, McGee L, Cahlon O, Hartsell W (2016) Proton therapy patterns-of-care and early outcomes for Hodgkin lymphoma: results from the proton collaborative group registry. Acta Oncol 55(11):1378–1380CrossRefPubMed

23.

www.nccn.org guidelines for Hodgkin Lymphoma version 3.2016, June 2016

24.

Ricardi U, Dabaja B, Hodgson DC (2017) Proton therapy in mediastinal Hodgkin lymphoma: moving from dosimetric prediction to clinical evidence. Ann Oncol 28(9):2049–2050CrossRefPubMed

25.

Filippi AR, Levis M, Parikh R, Hoppe B (2017) Optimal therapy for early stage Hodgkin’s lymphoma: risk adapting, response adapting, and role of radiotherapy. Curr Oncol Rep 19(5):34CrossRefPubMed

26.

Bonadonna G, Zucali R, Monfardini S, De Lena M, Uslenghi C (1975) Combination chemotherapy of Hodgkin’s disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer 36(1):252–259CrossRefPubMed

27.

Diehl V, Franklin J, Pfreundschuh M, Lathan B, Paulus U, Hasenclever D, Tesch H, Herrmann R, Dörken B, Müller-Hermelink HK, Dühmke E, Loeffler M, German Hodgkin's Lymphoma Study Group (2003) German Hodgkin’s lymphoma study group. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin’s disease. N Engl J Med 348(24):2386–2395CrossRefPubMed

28.

Viviani S, Zinzani PL, Rambaldi A, Brusamolino E, Levis A, Bonfante V, Vitolo U, Pulsoni A, Liberati AM, Specchia G, Valagussa P, Rossi A, Zaja F, Pogliani EM, Pregno P, Gotti M, Gallamini A, Rota Scalabrini D, Bonadonna G, Gianni AM, Michelangelo Foundation, Gruppo Italiano di Terapie Innovative nei Linfomi, Intergruppo Italiano Linfomi (2011) Michelangelo foundation, Gruppo Italiano di Terapie innovative nei L infomi. ABVD versus BEACOPP for Hodgkin’s lymphoma when high-dose salvage is planned. N Engl J Med 365(3):203–212CrossRefPubMed

29.

Merli F, Luminari S, Gobbi PG, Cascavilla N, Mammi C, Ilariucci F, Stelitano C, Musso M, Baldini L, Galimberti S, Angrilli F, Polimeno G, Scalzulli PR, Ferrari A, Marcheselli L, Federico M (2016) Long-term results of the HD2000 trial comparing ABVD versus BEACOPP versus COPP-EBV-CAD in untreated patients with advanced Hodgkin lymphoma: a study by Fondazione Italiana Linfomi. J Clin Oncol 34(11):1175–1181CrossRefPubMed

30.

Carde P, Karrasch M, Fortpied C et al (2016) Eight cycles of ABVD versus four cycles of BEACOPPescalated plus four cycles of BEACOPPbaseline in stage III to IV, international prognostic score ≥3, high risk Hodgkin lymphoma: first results of the phase III EORTC 2012 intergroup trial. J Clin Oncol 34(17):2018–2036CrossRef

31.

Mounier N, Brice P, Bologna S, Briere J, Gaillard I, Heczko M, Gabarre J, Casasnovas O, Jaubert J, Colin P, Delmer A, Devidas A, Bachy E, Nicolas-Virelizier E, Aoudjhane A, Humbrecht C, Andre M, Carde P, Lymphoma Study Association (LYSA) (2014) ABVD (8 cycles) versus BEACOPP (4 escalated cycles + 4 baseline): final results in stage III-IV low-risk Hodgkin lymphoma (IPS 0-2) of the LYSA H34 randomized trial. Ann Oncol 25:1622–1628CrossRefPubMed

32.

Skotez N, Will A, Monsef I et al (2017) Comparison of first-line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma. Cochrane Database Syst Rev 5:CD007941. Review

33.

Behringer K, Dhiel V (2005) Twenty-five years clinical trials of the German Hodgkin study group (GHSG). Eur J Haematol Suppl 66:21–25CrossRef

34.

Behringer K, Mueller H, Goergen H, Thielen I, Eibl AD, Stumpf V, Wessels C, Wiehlpütz M, Rosenbrock J, Halbsguth T, Reiners KS, Schober T, Renno JH, von Wolff M, van der Ven K, Kuehr M, Fuchs M, Diehl V, Engert A, Borchmann P (2013) Gonadal function and fertility in survivors after Hodgkin’s lymphoma treatment within the German Hodgkin study group HD3-HD15 trials. J Clin Oncol 31(2):231–239CrossRefPubMed

35.

Biggi A, Bergesio F, Chauvie S et al (2017) Concomitant semi-quantitative and visual analysis improves the predictive value on treatment outcome of interim 18F-fluorodeoxyglucose/positron emission tomography in advanced Hodgkin lymphoma. Q J Nucl Med Mol Imagine. https://doi.org/10.1093/annonc/mdx524

36.

Johnson P, Federico M, Kirkwood A, Fosså A, Berkahn L, Carella A, d’Amore F, Enblad G, Franceschetto A, Fulham M, Luminari S, O’Doherty M, Patrick P, Roberts T, Sidra G, Stevens L, Smith P, Trotman J, Viney Z, Radford J, Barrington S (2016) Adapted treatment guided by interim PET-CT scan in advanced Hodgkin’s lymphoma. N Engl J Med 374(25):2419–2429CrossRefPubMedPubMedCentral

37.

Press OW, Li H, Schöder H, Straus DJ, Moskowitz CH, LeBlanc M, Rimsza LM, Bartlett NL, Evens AM, Mittra ES, LaCasce AS, Sweetenham JW, Barr PM, Fanale MA, Knopp MV, Noy A, Hsi ED, Cook JR, Lechowicz MJ, Gascoyne RD, Leonard JP, Kahl BS, Cheson BD, Fisher RI, Friedberg JW (2016) US intergroup trial of response-adapted therapy for stage III to IV Hodgkin lymphoma using early interim fluorodeoxyglucose-positron emission tomography imaging: southwest oncology group S0816. J Clin Oncol 34(17):2020–2027CrossRefPubMedPubMedCentral

38.

Gallamini A, Tarella C, Viviani S, et al. (2018) Early chemotherapy intensification with escalated BEACOPP in advanced-stage Hodgkin lymphoma patients with a positive PET-CT after 2 ABVD cycles: long-term results of the GITIL/FIL HD 0607 trial. J Clin Oncol. in press

39.

Zinzani PL, Broccoli A, Gioia DM, Castagnoli A, Ciccone G, Evangelista A, Santoro A, Ricardi U, Bonfichi M, Brusamolino E, Rossi G, Anastasia A, Zaja F, Vitolo U, Pavone V, Pulsoni A, Rigacci L, Gaidano G, Stelitano C, Salvi F, Rusconi C, Tani M, Freilone R, Pregno P, Borsatti E, Sacchetti GM, Argnani L, Levis A (2016) Interim positron emission tomography response-adapted therapy in advanced-stage Hodgkin lymphoma: final results of the phase II part of the HD0801 study. J Clin Oncol 34(12):1376–1385CrossRefPubMed

40.

Borchman P, Goergen H, Kobe C et al (2017) PET-guided treatment in patients with advanced-stage Hodgkin’s lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by German Hodgkin study group. Lancet 6736(17):32134–32137

41.

Dann EJ, Bairey O, Bar-Shalom R, Mashiach T, Barzilai E, Kornberg A, Akria L, Tadmor T, Filanovsky K, Abadi U, Kagna O, Ruchlemer R, Abdah-Bortnyak R, Goldschmidt N, Epelbaum R, Horowitz NA, Lavie D, Ben-Yehuda D, Shpilberg O, Paltiel O (2017) Modification of initial therapy in early and advanced Hodgkin lymphoma, based on interim PET/CT is beneficial: a prospective multicentre trial of 355 patients. Br J Haematol 178(5):709–718CrossRefPubMed

42.

Casanovas O, Brice P, Bouabdallah R, et al. (2015) Randomised phase III study comparing an early PET driven treatment de-escalation to a not PET-monitored strategy in patients with advanced stages Hodgkin lymphoma: interim analysis of the AHL2011 Lysa study. ASH Meeting; abstract #577

43.

Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, Ramchandren R, Bartlett NL, Cheson BD, de Vos S, Forero-Torres A, Moskowitz CH, Connors JM, Engert A, Larsen EK, Kennedy DA, Sievers EL, Chen R (2012) Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol 30(18):2183–2189CrossRefPubMedPubMedCentral

44.

Chen R, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, Connors JM, Engert A, Larsen EK, Huebner D, Fong A, Younes A (2016) Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. Blood 128(12):1562–1566CrossRefPubMedPubMedCentral

45.

Younes A, Connors JM, Park SI, Fanale M, O'Meara MM, Hunder NN, Huebner D, Ansell SM (2013) Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study. Lancet Oncol 14(13):1348–1356CrossRefPubMed

46.

Connors JM, Ansell SM, Fanale M, Park SI, Younes A (2017) Five-year follow-up of brentuximab vedotin combined with ABVD or AVD for advanced-stage classical Hodgkin lymphoma. Blood 130(11):1375–1377CrossRefPubMedPubMedCentral

47.

Connors JM, Jurczak W, Straus DJ, Ansell SM, Kim WS, Gallamini A, Younes A, Alekseev S, Illés Á, Picardi M, Lech-Maranda E, Oki Y, Feldman T, Smolewski P, Savage KJ, Bartlett NL, Walewski J, Chen R, Ramchandren R, Zinzani PL, Cunningham D, Rosta A, Josephson NC, Song E, Sachs J, Liu R, Jolin HA, Huebner D, Radford J, ECHELON-1 Study Group (2018) Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin’s lymphoma. N Engl J Med 378:331–344CrossRefPubMed

48.

Eichenauer DA, Plütschow A, Kreissl S, Sökler M, Hellmuth JC, Meissner J, Mathas S, Topp MS, Behringer K, Klapper W, Kuhnert G, Dietlein M, Kobe C, Fuchs M, Diehl V, Engert A, Borchmann P (2017) Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin’s lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group. Lancet Oncol 18(12):1680–1687CrossRefPubMed

49.

Friedberg JW, Forero-Torres A, Bordoni RE et al (2017; blood-2017-06-787200) Frontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged ≥60 years with HL. Blood. https://doi.org/10.1182/blood-2017-06-787200

50.

Santoro A, Magagnoli M, Spina M, et at. (2007) Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin’s lymphoma. Haematologica 92:35–41

51.

Moskowitz CH, Nimer SD, Zelenetz AD, Trippett T, Hedrick EE, Filippa DA, Louie D, Gonzales M, Walits J, Coady-Lyons N, Qin J, Frank R, Bertino JR, Goy A, Noy A, O'Brien JP, Straus D, Portlock CS, Yahalom J (2001) A 2-step comprehensive high-dose chemo-radiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood 97:616–623CrossRefPubMed

52.

Josting A, Mùller H, Borchmann P et al (2010) Dose intensity of chemotherapy in patients with relapsed Hodgkin’s lymphoma. JClinOncol 28:5074–5080CrossRef

53.

Linch DC, Winfield D, Goldstone AH et al (1993) Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin’s disease: results of a BNLI randomized trial. Lancet 341:1051–1054CrossRefPubMed

54.

Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M, Boissevain F, Zschaber R, Müller P, Kirchner H, Lohri A, Decker S, Koch B, Hasenclever D, Goldstone AH, Diehl V (2002) Aggressive conventional chemotherapy compared with high-dose chemotherapy and autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease: a randomised trial. Lancet 359:2065–2071CrossRefPubMed

55.

Rancea M, von Tresckow B, Monsef L et al (2014) High-dose chemotherapy followed by autologous stem-cell transplantation for patients with relapsed or refractory Hodgkin lymphoma. A systematic review with meta-analysis. Crit Rev Oncol Hematol 92:1–10CrossRefPubMed

56.

Santoro A, Mazza R, Pulsoni A, Re A, Bonfichi M, Zilioli VR, Salvi F, Merli F, Anastasia A, Luminari S, Annechini G, Gotti M, Peli A, Liberati AM, di Renzo N, Castagna L, Giordano L, Carlo-Stella C (2016) Bendamustine in combination with gemcitabine and Vinorelbine is an effective regimen as induction chemotherapy before autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma: final Resultsof a multicenter phase II study. J Clin Oncol 34:3293–3299CrossRefPubMed

57.

Shah GL, Bantilan KS, Verws SL et al (2015) Risk factors predicting outcomes for primary refractory Hodgkin lymphoma patients treated with salvage chemotherapy and autologous stem cell transplantation. Blood 126:520–520CrossRef

58.

Younes A, Barlett NL, Leonard JP et al (2010) Brentuximab vedotin (SGN-35) for relapsed CD-30 positive lymphoma. N Engl J Med 363:1812–1821CrossRefPubMed

59.

Gopal AK, Chen R, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, Connors JM, Engert A, Larsen EK, Chi X, Sievers EL, Younes A (2015) Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma. Blood 125:1236–1243CrossRefPubMedPubMedCentral

60.

Pellegrini C, Broccoli A, Pulsoni A et al (2017) Italian real life experience: results of a large observational study on 234 relapsed/refractory Hodkin’s lymphoma. Advance Publications, Oncotarget, p 2017

61.

Moskowitz CH, Shoder H, Yahalom J et al (2015) PET-adapted sequential salvage therapy with brentuximab-vedotin followed by augment Ifosamide, carboplatin and etoposide for patients with relapsed and refractory Hodgkin’s lymphoma: a no randomized, open-label, single-centre, phase 2 study. Lancet Oncol 16:238–239CrossRef

62.

Chen R, Palmer GM, Martin P et al (2015) Results of a multicenter phase II trial of brentuximab vedotin as second-line therapy before autologous transplantion in relapsed/refractory Hodgkin lymphoma. Biol Blood Marrow Transplant 21(12):2136–2140CrossRefPubMedPubMedCentral

63.

La Casce AS, Bociek G, Saws A et al (2015) Brentuximab vedotin plus bendamustine: a higly active salvage treatment regiment for patients with relapsed or refractory Hodgkin lymphoma. Blood 126:3982–3982

64.

Gallamini A, Bijou F, Viotti J et al (2017) Brentuximab vedotin and bendamustine is a feasible and effective drug combination as first-line treatment of Hodgkin lymphoma in the elderly (HALO study). XIV International Conference on Malignant Limphoma, Lugano. Haematol Oncol 35(S2):170 abstr N168CrossRef

65.

Garcia-Sanz R, Sureda A, Alonso-Alvarez S et al (2015) Evaluation of the regiment Brentuximab Vedotin plus ESHAP (BRESHAP) in refractory or relapsed Hodgkin lymphoma patients: preliminary results of a phase I-II trial from the Spanish Group of lymphoma and bone marrow transplantation (GELTAMO). Blood 126:582–582CrossRef

66.

Moskowitz CH, Nademanee A, Masszi T, Agura E, Holowiecki J, Abidi MH, Chen AI, Stiff P, Gianni AM, Carella A, Osmanov D, Bachanova V, Sweetenham J, Sureda A, Huebner D, Sievers EL, Chi A, Larsen EK, Hunder NN, Walewski J (2015) AETHERA study group brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin’s lymphoma at risk of relapse or progression: a randomized, double-blind, placebo controlled phase 3 trial. Lancet 385:1853–1862CrossRefPubMed

67.

Sweethenam J, Walewski J, Nadamanee A, et al. (2015) Update efficacy and safety data from the ATHERA trial of consolidation with brentuximab vedotin after autologous stem cell transplantation(ASCT) in Hodgkin lymphoma patients at high risk of relapse. ASH (abstract 3172)

68.

Moskowitz G, Sweethenam j, Chen A, et al. (2016) Brentuximab vedotin after autologous stem cell transplant (ASCT) yields the strongest benefit in Hodgkin lymphoma(HL) patients with ≥2 risk factors: results of a multivariate analysis. Intern. Symposium on Hodgkin Lymphoma, Colonia (Abstract No.0044)

69.

Hude I, Sasse S, Engert A, Brockelmann PJ (2017) The emerging role of immune checkpoint inhibitors in malignant lymphoma. Haematologica 102:30–42CrossRefPubMedPubMedCentral

70.

Green MR, Monti S, Sj R et al (2010) Integrative analysis reveals selective 9p.24.1 amplification, increased PD-1 ligend expression and further induction via JAK2 in nodular schlerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood 116(17):3268–3277CrossRefPubMedPubMedCentral

71.

Roemer MG, Advani RH, Ligon AH et al (2016) PD-L1 and PD-L2 genetic alterations define classic Hodgkin lymphoma and predict outcome. J Clin Oncol 34:2690–2697CrossRefPubMedPubMedCentral

72.

Bashey A, Medina B, Corringam S et al (2009) CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation. Blood 113:1581–1588CrossRefPubMedPubMedCentral

73.

Diefenbach CS, Hong F, Cohen JB, et al. (2015) Preliminary safety and efficacy of the combination of Brentuximab Vedotin and Ipilimumab in relapsed/refractory Hodgkin lymphoma: a trial of the ECOG-ACRIN cancer research group (E4412). Blood: 126; abstract 585

74.

Ansell SM, Lesokhin AM, Borello I et al (2015) PD blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N Engl J Med 372:311–319CrossRefPubMed

75.

Younes A, Santoro A, Shipp M, Zinzani PL, Timmerman JM, Ansell S, Armand P, Fanale M, Ratanatharathorn V, Kuruvilla J, Cohen JB, Collins G, Savage KJ, Trneny M, Kato K, Farsaci B, Parker SM, Rodig S, Roemer MGM, Ligon AH, Engert A (2016) Nivolumab for classical Hodgkin’s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol 17:1283–1294CrossRefPubMedPubMedCentral

76.

Armand P, Shipp MA, Ribrag V, Michot JM, Zinzani PL, Kuruvilla J, Snyder ES, Ricart AD, Balakumaran A, Rose S, Moskowitz CH (2016) Programed death blockade with Pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure. J Clin Oncol 34:3733–3739CrossRefPubMedPubMedCentral

77.

Moskowitz C, Zinzani PL, Fanale MA, et al. (2016) Multicohort phase 2 study of Pembrolizumab for relapsed/refractory classical Hodgkin lymphoma: Keynote-087 EHA 21 (abstract s794) Copenhagen, Denmark.

78.

Cheson BD, Ansel S, Schwartz L et al (2017) Refinement of the Lugano classification lymphoma response criteria in the era of immunomodulatory therapy. Blood 128:2489–2496CrossRef

79.

Sureda A, Bader P, Cesaro S et al (2015) Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015. Bone Marrow Transplant 50(8):1037–1056CrossRefPubMed

80.

Gajewski JL, Phillips GL, Sobocinski KA, Armitage JO, Gale RP, Champlin RE, Herzig RH, Hurd DD, Jagannath S, Klein JP, Lazarus HM, McCarthy PL Jr, Pavlovsky S, Peterson FB, Rowlings PA, Russell JA, Silver SM, Vose JM, Wiernik PH, Bortin MM, Horowitz MM (1996) Bone marrow transplants from HLA-identical siblings in advanced Hodgkin’s disease. J Clin Oncol Off J Am Soc Clin Oncol 14(2):572–578CrossRef

81.

Milpied N, Fielding AK, Pearce RM, Ernst P, Goldstone AH (1996) Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin’s disease. European Group for Blood and Bone Marrow Transplantation. J Clin Oncol Off J Am Soc Clin Oncol 14(4):1291–1296CrossRef

82.

Sureda A, Robinson S, Canals C, Carella AM, Boogaerts MA, Caballero D, Hunter AE, Kanz L, Slavin S, Cornelissen JJ, Gramatzki M, Niederwieser D, Russell NH, Schmitz N (2008) Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin’s lymphoma: an analysis from the lymphoma working party of the European group for blood and marrow transplantation. J Clin Oncol 26(3):455–462CrossRefPubMed

83.

Sureda A, Canals C, Arranz R, et al. (2012) Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin’s lymphoma. Results of the HDR-ALLO study—a prospective clinical trial by the Grupo Espanol de Linfomas/Trasplante de Medula Osea (GEL/TAMO) and the lymphoma working party of the European group for blood and marrow transplantation. Haematologica 97(2):310–317CrossRef

84.

Robinson SP, Sureda A, Canals C, Russell N, Caballero D, Bacigalupo A, Iriondo A, Cook G, Pettitt A, Socie G, Bonifazi F, Bosi A, Michallet M, Liakopoulou E, Maertens J, Passweg J, Clarke F, Martino R, Schmitz N, on behalf of the Lymphoma Working Party of the EBMT (2009) Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin’s lymphoma: identification of prognostic factors predicting outcome. Haematologica 94(2):230–238CrossRefPubMed

85.

Peggs KS, Kayani I, Edwards N, Kottaridis P, Goldstone AH, Linch DC, Hough R, Morris EC, Fielding A, Chakraverty R, Thomson KJ, Mackinnon S (2011) Donor lymphocyte infusions modulate relapse risk in mixed chimeras and induce durable salvage in relapsed patients after T-cell–depleted allogeneic transplantation for Hodgkin’s lymphoma. J Clin Oncol 29(8):971–978CrossRefPubMed

86.

Raiola AM, Dominietto A, Ghiso A, di Grazia C, Lamparelli T, Gualandi F, Bregante S, van Lint MT, Geroldi S, Luchetti S, Ballerini F, Miglino M, Varaldo R, Bacigalupo A (2013) Unmanipulated haploidentical bone marrow transplantation and Posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning. Biol Blood Marrow Transplant 19(1):117–122CrossRefPubMed

87.

Ciurea SO, Zhang M-J, Bacigalupo AA, Bashey A, Appelbaum FR, Aljitawi OS, Armand P, Antin JH, Chen J, Devine SM, Fowler DH, Luznik L, Nakamura R, O'Donnell PV, Perales MA, Pingali SR, Porter DL, Riches MR, Ringden OTH, Rocha V, Vij R, Weisdorf DJ, Champlin RE, Horowitz MM, Fuchs EJ, Eapen M (2015) Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia. Blood 126(8):1033–1040CrossRefPubMedPubMedCentral

88.

Kanate AS, Mussetti A, Kharfan-Dabaja MA, Ahn KW, DiGilio A, Beitinjaneh A, Chhabra S, Fenske TS, Freytes C, Gale RP, Ganguly S, Hertzberg M, Klyuchnikov E, Lazarus HM, Olsson R, Perales MA, Rezvani A, Riches M, Saad A, Slavin S, Smith SM, Sureda A, Yared J, Ciurea S, Armand P, Salit R, Bolanos-Meade J, Hamadani M (2016) Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors. Blood 127(7):938–947CrossRefPubMedPubMedCentral

89.

Ghosh N, Karmali R, Rocha V, Ahn KW, DiGilio A, Hari PN, Bachanova V, Bacher U, Dahi P, de Lima M, D’Souza A, Fenske TS, Ganguly S, Kharfan-Dabaja MA, Prestidge TD, Savani BN, Smith SM, Sureda AM, Waller EK, Jaglowski S, Herrera AF, Armand P, Salit RB, Wagner-Johnston ND, Fuchs E, Bolaños-Meade J, Hamadani M (2016) Reduced-intensity transplantation for lymphomas using haploidentical related donors versus HLA-matched sibling donors: a Center for International Blood and Marrow Transplant Research Analysis. J Clin Oncol 34(26):3141–3149CrossRefPubMedPubMedCentral

90.

Castagna L, Bramanti S, Furst S, Giordano L, Crocchiolo R, Sarina B, Mauro E, Morabito L, Bouabdallah R, Coso D, Balzarotti M, Broussais F, el-Cheikh J, Stella CC, Brusamolino E, Blaise D, Santoro A (2014) Non myeloablative conditioning, unmanipulated haploidentical SCT and post-infusion CY for advanced lymphomas. Bone Marrow Transplant 49(12):1475–1480CrossRefPubMed

91.

Martínez C, Gayoso J, Canals C, Finel H, Peggs K, Dominietto A, Castagna L, Afanasyev B, Robinson S, Blaise D, Corradini P, Itälä-Remes M, Bermúdez A, Forcade E, Russo D, Potter M, McQuaker G, Yakoub-Agha I, Scheid C, Bloor A, Montoto S, Dreger P, Sureda A, Lymphoma Working Party of the European Group for Blood and Marrow Transplantation (2017) Post-transplantation cyclophosphamide-based haploidentical transplantation as alternative to matched sibling or unrelated donor transplantation for Hodgkin lymphoma: a registry study of the lymphoma working party of the European Society for blood and marrow transplantation. J Clin Oncol 35(30):3425–3432CrossRefPubMed

92.

Chen F, Palmer JM, Tsa NC et al (2014) Berentuximab vedotin is associated with improved progression-free survival after allogeneic transplantation for Hodgkin lymphoma. Biol Blood Marrow Tranplant 20(11):1864–1868CrossRef

93.

Merryman RW, Kim HT, Zinzani PL, Carlo-Stella C, Ansell SM, Perales MA, Avigdor A, Halwani AS, Houot R, Marchand T, Dhedin N, Lescaut W, Thiebaut-Bertrand A, François S, Stamatoullas-Bastard A, Rohrlich PS, Labussière Wallet H, Castagna L, Santoro A, Bachanova V, Bresler SC, Srivastava A, Kim H, Pesek E, Chammas M, Reynolds C, Ho VT, Antin JH, Ritz J, Soiffer RJ, Armand P (2017) Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma. Blood 129(10):1380–1388CrossRefPubMedPubMedCentral

94.

Ram R, Gooley TA, Maloney DG, Press OW, Pagel JM, Petersdorf SH, Shustov AR, Flowers MED, O’Donnell P, Sandmaier BM, Storb RF, Gopal AK (2011) Histology and time to progression predict survival for lymphoma recurring after reduced-intensity conditioning and allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 17(10):1537–1545CrossRefPubMedPubMedCentral

95.

Wudhikarn K, Brunstein CG, Bachanova V, Burns LJ, Cao Q, Weisdorf DJ (2011) Relapse of lymphoma after allogeneic hematopoietic cell transplantation: management strategies and outcome. Biol Blood Marrow Transplant 17(10):1497–1504CrossRefPubMedPubMedCentral

96.

Castagna L, Sarina B, Crocchiolo R, Bramanti S, Furst S, Devillier R, Coso D, Bouabdallah R, Mokart D, Morabito L, Harbi S, Giordano L, Rimondo A, Jean Weiller P, Carlo-Stella C, Santoro A, Chabannon C, Blaise D (2016) Outcomes of Hodgkin lymphoma patients who relapse after allogeneic stem cell transplantation. Bone Marrow Transplant 51(12):1644–1646CrossRefPubMed

97.

Carlo-Stella C, Ricci F, Dalto S, Mazza R, Malagola M, Patriarca F, Viviani S, Russo D, Giordano L, Castagna L, Corradini P, Santoro A (2015) Brentuximab vedotin in patients with Hodgkin lymphoma and a failed allogeneic stem cell transplantation: results from a named patient program at four Italian centers. Oncologist 20(3):323–328CrossRefPubMedPubMedCentral

98.

Bashey A, Medina B, Corringham S, Pasek M, Carrier E, Vrooman L, Lowy I, Solomon SR, Morris LE, Holland HK, Mason JR, Alyea EP, Soiffer RJ, Ball ED (2008) CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation. Blood 113(7):1581–1588CrossRefPubMed

99.

Davids MS, Kim HT, Bachireddy P, et al (2016) Ipilimumab for patients with relapse after allogeneic transplantation. N Engl J Med 375(2):143–153CrossRef

100.

Herbaux C, Gauthier J, Brice P, Drumez E, Ysebaert L, Doyen H, Fornecker L, Bouabdallah K, Manson G, Ghesquières H, Tabrizi R, Hermet E, Lazarovici J, Thiebaut-Bertrand A, Chauchet A, Demarquette H, Boyle E, Houot R, Yakoub-Agha I, Morschhauser F (2017) Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma. Blood 129(18):2471–2478CrossRefPubMed

101.

Haverkos BM, Abbott D, Hamadani M, Armand P, Flowers ME, Merryman R, Kamdar M, Kanate AS, Saad A, Mehta A, Ganguly S, Fenske TS, Hari P, Lowsky R, Andritsos L, Jagasia M, Bashey A, Brown S, Bachanova V, Stephens D, Mineishi S, Nakamura R, Chen YB, Blazar BR, Gutman J, Devine SM (2017) PD-1 blockade for relapsed lymphoma post–allogeneic hematopoietic cell transplant: high response rate but frequent GVHD. Blood 130:221–228CrossRefPubMedPubMedCentral

Titel: Treatment of classical Hodgkin lymphoma in the era of brentuximab vedotin and immune checkpoint inhibitors
verfasst von: A. M. Carella
P. Corradini
A. Mussetti
U. Ricardi
U. Vitolo
S. Viviani
Publikationsdatum: 25.05.2018
Verlag: Springer Berlin Heidelberg
Erschienen in: Annals of Hematology / Ausgabe 8/2018
Print ISSN: 0939-5555
Elektronische ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-018-3366-x

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

23.04.2024 | Ablationstherapie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Treatment of classical Hodgkin lymphoma in the era of brentuximab vedotin and immune checkpoint inhibitors

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

Europäische Ernährungsgewohnheiten: Das sind die häufigsten Fehler

Hinter dieser Appendizitis steckte ein Erreger

Demenzkranke durch Antipsychotika vielfach gefährdet

Update Innere Medizin

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2018

Brentuximab vedotin is effective for rheumatoid arthritis in a patient with relapsed methotrexate-associated Hodgkin lymphoma

Outcomes of patients with myelofibrosis treated with compassionate use pacritinib: a sponsor-independent international study

Major response of PNH to an AML chemotherapy protocol

Light chain monoclonal gammopathy of undetermined significance is characterized by a high disappearance rate and low risk of progression on longitudinal analysis

Diffuse large B cell lymphoma (DLBCL): bilateral vanishing tibiae

Efficacy and safety of decitabine against cutaneous granuloblastic sarcoma: a case report

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

Europäische Ernährungsgewohnheiten: Das sind die häufigsten Fehler

Hinter dieser Appendizitis steckte ein Erreger

Demenzkranke durch Antipsychotika vielfach gefährdet

Update Innere Medizin